Senturk 1997.

Methods	Generation of allocation sequence: unclear (no description). Allocation concealment: unclear (no description). Double blinding: inadequate (not blinding). Follow up: adequate (six patients from UDCA plus IFN group; four patients from IFN group). Sample size calculation: no information. Intention‐to‐treat analysis: not performed.
Participants	Country: Turkey. Type of hepatitis: chronic hepatitis C. INCLUSION CRITERIA ‐ persistent serum ALT elevation of two times or more of the upper normal limit for at least six months preceding treatment; ‐ serum anti‐HCV and HCV RNA positive; ‐ absence of HBsAg; ‐ liver biopsy findings of chronic hepatitis. EXCLUSION CRITERIA ‐ patients with signs of decompensated cirrhosis such as ascites, oesophageal varices, and hepatic encephalopathy. PARTICIPANTS ‐ UDCA plus IFN group (n =45): Mean age (years) 50 (19‐69). Ratio of sex (M/F) 22/23. Proportion of patients with cholestasis: no information. Proportion of patients with cirrhosis: no information. ‐ IFN group: Mean age (years) 46 (23‐73). Ratio of sex (M/F) 23/26.
Interventions	UDCA plus IFN group: UDCA ‐ Dose: 500 mg/day; ‐ Route: orally; ‐ Timing: two times per day; ‐ Duration: six months. Alpha IFN ‐ Dose: three million units; ‐ Route: no described; ‐ Timing: three times per week; ‐ Duration: six months. IFN group: Alpha IFN ‐ Dose: three million units; ‐ Route: no described; ‐ Timing: three times per week; ‐ Duration: six months.
Outcomes	‐ Normalisation of serum ALT at the end of six months treatment.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear